Adrenergic Uptake Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Purchase Option

$ 4400
$ 6600
$ 8900

Adrenergic uptake inhibitors market size was valued at USD XX million in 2023 and is expected to grow at XX% CAGR over the forecast years 2024 – 2030. The adrenergic nervous system is a part of the autonomic nervous system that uses epinephrine or norepinephrine as its neurotransmitter. Adrenergic receptor, a receptor type for epinephrine and norepinephrine; subtypes include α1, α2, β1, β2, and β3 receptors. Adrenergic uptake inhibitors drugs primarily target the reuptake process of neurotransmitters, specifically norepinephrine (noradrenaline) and sometimes dopamine, by inhibiting the activity of the transporter proteins responsible for their reuptake. The mechanism of action of adrenergic uptake inhibitors involves blocking the reuptake of norepinephrine and/or dopamine from the synaptic cleft back into the presynaptic neuron, thereby increasing the concentration of these neurotransmitters in the synaptic space. This results in increased neurotransmitter signaling and prolonged activation of adrenergic receptors on the postsynaptic neuron. Adrenergic Uptake Inhibitors are used to treat CNS disorders, mood disorders, back pain, low back pain, and neurologic manifestations to name a few. Increased prevalence of neurological disorders and changing lifestyles are the key drivers for the Adrenergic Uptake Inhibitors market.

For instance, According to the World Health Organization 2023, an estimated 3.8% of the population experience depression, including 5% of adults (4% among men and 6% among women) and 5.7% of adults older than 60 years. approximately 280 million people in the world have depression. Depression is about 50% more common among women than among men. The launch of newer products by the market players could seek opportunities that influence extensive research and development in Adrenergic Uptake Inhibitors. For instance, Axsome Therapeutics launched Auvelity (Bupropion/Dextromethorphan) to treat depression. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, Otsuka’s OPC-64005 for the treatment of depression is under the various stages of clinical studies.

Key Market Developments:

In August 2022, Axsome Therapeutics received FDA approval for its Auvelity (Dextromethorphan Hbr -Bupropion Hcl) extended-release tablet for the treatment of major depressive disorder.

Approved Drug Molecules and Brand Names for Adrenergic Uptake Inhibitors:

Auvelity (Dextromethorphan Hbr -Bupropion Hcl) Extended-Release Tablet

Drugs under the Pipeline for Adrenergic Uptake Inhibitors:

  • Esreboxetine (AXS-14)
  • Dasotraline (SEP-225289)
  • Axomadol (EN3324)
  • Reboxetine/Oxybutynin (AD128)
  • Nolazol (Mazindol CR)
  • OPC-64005
  • Celecoxib/Tramadol (YYC301)
  • Methylphenidate/Naltrexone (AVK-001)

Clinical Activity and Developments of Adrenergic Uptake Inhibitors:

Till July 2023, more than 12 companies have approximately 13 molecules targetting the many CNS disorders. For these molecules, more than 150 clinical trials are being conducted; most are in phase-2 and phase-3 clinical trials by players across the globe. For instance,

  • In June 2021, Pfizer completed phase 2, an 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-Reboxetine administered once daily in patients with fibromyalgia.

Molecule Name

Number of Studies

Esreboxetine (AXS-14)


Dasotraline (SEP-225289)


Axomadol (EN3324)


Reboxetine/Oxybutynin (AD128)


Nolazol (Mazindol CR)


Target Indication Analysis of Adrenergic Uptake Inhibitors

The molecules such as Auvelity (Dextromethorphan Hbr -Bupropion Hcl) Extended-Release Tablet were developed by Axsome Therapeutics is an uncompetitive N-methyl D-aspartate (NDMA) receptor antagonist and sigma-1 receptor agonist and bupropion hydrochloride, an aminoketone and CYP450 2D6 inhibitor. Auvelity is specifically indicated for the treatment of major depressive disorder (MDD) in adults. Auvelity is supplied as a tablet for oral administration.

Frequently Asked Questions

Auvelity (Bupropion/Dextromethorphan) is the only FDA-approved Adrenergic Uptake Inhibitors.

Total net product sales for molecule Auvelity by Axsome Therapeutics was USD 15.7 million in the first quarter of FY2023.

Major market players include Axsome Therap, Pfizer, and Sumitomo Pharma are few leading market players in Adrenergic Uptake Inhibitors.

CNS disorders, mood disorders, back pain, low back pain, and neurologic manifestations, etc are the major Indications for Adrenergic Uptake Inhibitors.

There are a total of 9 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Axsome Therap
  • Pfizer
  • Sumitomo Pharma
  • Endo
  • NLS Pharma
  • Apnimed
  • Avekshan
  • Otsuka

Adjacent Markets